Skip to content

Sudden Cardiac Death Stratification in Myotonic Dystrophy Type 1 Patients

The Electrophysiological Study Guided ICD Strategy in Prevention of Arrhythmic Cardiac Death in Myotonic Dystrophy Type 1 Patients With Conduction System Disease (ACADEMY 1 Study)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03784586
Acronym
ACADEMY 1
Enrollment
70
Registered
2018-12-24
Start date
2012-02-01
Completion date
2023-05-31
Last updated
2021-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myotonic Dystrophy 1, Sudden Cardiac Death

Keywords

Arrhythmias, electrophisiological study, primary prevention

Brief summary

The aim of the study is to evaluate if the electrophysiological study (EPS) guided therapy, including the prophylactic implantation of implantable cardioverter defibrillator (ICD), in inducible patients, is able to improve survival in comparison with conventional therapy (CONV strategy) in Myotonic Dystrophy type 1 patients with conduction disorders.

Detailed description

Trial design: This is a double-arm prospective observational study. Patient population: To be included in the study, DM1 patients had to have at least 18 years old, LVEF \>35% on two-dimensional echocardiography, permanent pacing indication after non-invasive electrocardiographic evaluation or invasive EPS evaluation, according to the current guidelines. The following exclusion criteria were applied: electrolyte imbalance, thyroid disorders, prior cardiac surgery, prior cardiac arrest, prior spontaneous sustained ventricular arrhythmias, absuntion of antiarrhythmic drugs or medication known to affect cardiac conduction. All eligible DM1 patients underwent EPS for programmed ventricular stimulation; those in whom a sustained ventricula arrhythmia was inducible underwent subsequently ICD implantation. Non-inducible DM1 patients did not receive an ICD and underwent pacemaker implantation. Endpoints: The primary endpoint was all-cause mortality. Secondary end-points were sudden death (SD), death due to cardiac arrhythmias, ICD interventions and arrhythmic events in implanted patients.

Interventions

None listed

Sponsors

University of Campania Luigi Vanvitelli
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* MD1 diagnosis genetically confirmed * LVEF \>35% on two-dimensional echocardiography * Permanent pacing indication according to the current guidelines

Exclusion criteria

* Electrolyte imbalance * Thyroid disorders * Prior cardiac surgery * Prior cardiac arrest * Prior spontaneous sustained ventricular arrhythmias

Design outcomes

Primary

MeasureTime frame
Sudden Cardiac Death24 months

Secondary

MeasureTime frame
All-cause mortality24 months

Countries

Italy

Contacts

Primary ContactVincenzo Russo, MD,PhD
v.p.russo@libero.it0817064149
Backup ContactAndrea Antonio Papa, MD
andreaantoniopapa@libero.it0817065158

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026